1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Starpharma Holdings Limited

Starpharma Holdings Limited

SPL.AX
Starpharma Holdings LimitedAU flagAustralian Securities Exchange
0.72
AUD
+0.00
- -
305.55MMarket Cap
Starpharma Holdings Limited
SPL.AX
(Australian Securities Exchange)

Recent

price

0.72

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.01
- -
- -
- -
- -
- -
0.01
0.01
0.01
- -
0.02
- -
0.01
0.01
0.02
0.01
Revenue per Share
-0.03
-0.04
-0.05
-0.02
-0.05
-0.06
-0.07
0.02
-0.03
-0.04
-0.04
-0.05
-0.04
-0.04
-0.02
-0.02
Basic EPS, GAAP
-0.02
-0.03
-0.04
-0.04
-0.04
-0.05
-0.05
-0.05
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.14
0.11
0.17
0.15
0.1
0.1
0.11
0.14
0.11
0.07
0.03
0.1
0.05
0.02
- -
-0.03
Book Value per Share
0.1
0.07
0.15
0.13
0.09
0.09
0.12
0.17
0.14
0.11
0.08
0.16
0.12
0.09
0.07
0.05
Tangible Book Value per Share
226
243
268
283
284
310
345
368
370
371
372
397
407
409
411
417
Basic Weighted Avg Shares
1
1
- -
- -
- -
1
4
3
4
2
6
2
5
3
8
5
Sales/Revenue/Turnover
-894.87
-1,101.84
-40,118.18
-43,420
-6,118.68
-2,619.28
-638.22
-560.13
-308
-946.15
-276.33
-1,243.33
-378.3
-620.48
-129.65
-244.26
Operating Margin (%)
2
2
1
1
1
1
1
1
- -
- -
1
1
1
1
1
1
Depreciation Expense
-6
-9
-14
-5
-15
-19
-23
8
-10
-14
-15
-20
-16
-16
-8
-10
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-454.27
-780.59
-31,040.91
-26,145
-5,360.81
-2,356.97
-592.81
274.06
-269.81
-863.36
-243.3
-1,097.44
-345.02
-532.09
-98.5
-203.38
Profit Margin (%)
22
18
39
37
25
28
41
60
52
41
30
60
50
33
26
17
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
7
3
2
1
LT Debt
35
28
49
46
33
38
49
61
53
42
31
62
48
35
28
19
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-23.54
-30.46
-37.19
-11.72
-41.48
-65.59
-65.42
18.28
-22.87
-43.55
-80.19
-80.2
-53.55
-109.26
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.74%
-0.63%
-32.43%
Free Cash Flow
2.58%
34.55%
-52.81%
Net Income, GAAP
-31.27%
-2.47%
22.35%
Sales/Revenue/Turnover
78.44%
38.85%
-40.74%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3
2024
- -
- -
- -
- -
8
2025
- -
- -
- -
- -
5

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.04
2024
- -
- -
- -
- -
-0.02
2025
- -
- -
- -
- -
-0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
GRAIL Inc. (GRAL)
Seer, Inc. (SEER)
ContraFect Corp. (CFRXQ)
Mineralys Therapeutics, Inc. (MLYS)
Maze Therapeutics, Inc. (MAZE)
Intellia Therapeutics, Inc. (NTLA)
Business
Starpharma Holdings Limited (SPL.AX) develops and commercializes dendrimer nanotechnology platforms for applications in pharmaceuticals, antiviral treatments, and agricultural technologies. The company offers core products and services including VivaGel, a non-hormonal vaginal microbicide for bacterial vaginosis treatment; dendrimer-based antiviral gels and coatings for preventing HIV, herpes, and influenza transmission; and targeted drug delivery systems using Priostar dendrimers for oncology and other therapeutics; as well as agricultural solutions like AgroStar dendrimers for enhanced crop protection and delivery of active ingredients. Starpharma operates primarily in the biotechnology and nanotechnology sectors, targeting pharmaceutical companies, healthcare providers, and agribusinesses across Australia, the United States, Europe, and Asia-Pacific regions. Founded in 1996 and headquartered in Melbourne, Australia, the company maintains strategic partnerships with global firms such as GSK and Janssen for product development and commercialization, with no major subsidiaries or parent relationships publicly noted. In recent developments within the last two years, Starpharma expanded its antiviral portfolio through clinical advancements in dendrimer nasal sprays for COVID-19 prevention and secured new licensing agreements for VivaGel in additional international markets, alongside ongoing funding from government grants and investor rounds to support Phase III trials and manufacturing scale-up.